All In Biotech

Drug Trial Radar · NCT06534411

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,023 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,023

Actual

Start

Nov 5, 2024

Primary completion

Jun 2, 2026

Study completion Jul 9, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Aug 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • CagrilintideDrug

    Participants will receive once-weekly cagrilintide subcutaneously.

  • SemaglutideDrug

    Participants will receive once-weekly semaglutide subcutaneously.

  • TirzepatideDrug

    Participants will receive once-weekly tirzepatide subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Haemoglobin (HbA1c)Time frame: From baseline (week 0) to end of treatment (week 60)
  2. Relative Change in Body WeightTime frame: From baseline (week 0) to end of treatment (week 60)

Locations

163 sites in 14 countries. Site status is shown where the registry gives one.

  • Cahaba Research

    Pelham, Alabama

  • Velocity Clinical Research-Phoenix

    Phoenix, Arizona

  • AES Tucson DRS

    Tucson, Arizona

  • Woodland Int. Research Group

    Little Rock, Arkansas

  • Velocity Clin Res-Chula Vista

    Chula Vista, California

  • John Muir Physicians Network

    Concord, California

  • Diabetes & Endocrine Specialists - La Mesa

    La Mesa, California

  • Velocity Clin Research LA

    Los Angeles, California

  • Desert Oasis Healthcare

    Palm Springs, California

  • Velocity Clin Res Santa Ana

    Santa Ana, California

  • Velocity Clin Res - Panorama

    Van Nuys, California

  • Optumcare Clinical Trials,LLC-Golden

    Colorado Springs, Colorado

  • FEME Medical LLC

    Washington D.C., District of Columbia

  • Tampa Bay Medical Research

    Clearwater, Florida

  • AGA Clinical Trial

    Hialeah, Florida

  • Bioclinical Research Alliance

    Miami, Florida

  • New Horizon Research Center

    Miami, Florida

  • South Broward Research LLC

    Miramar, Florida

  • West Orange Endocrinology

    Ocoee, Florida

  • Optimal Research Sites

    Orange City, Florida

  • Center for Diab,Obes & Metab

    Pembroke Pines, Florida

  • Javara Inc. / Privia Medical Group Georgia LLC

    Fayetteville, Georgia

  • Clinical Invest Special_Gurnee

    Gurnee, Illinois

  • Iowa Diabetes & Endo Res Ctr

    West Des Moines, Iowa

  • Cotton-Oneill Diabetes and End

    Topeka, Kansas

  • AES Minneapolis DRS

    Richfield, Minnesota

  • Velocity Clin Res Gulfport

    Gulfport, Mississippi

  • AES St. Louis DRS

    St Louis, Missouri

  • Univ of Nebraska Medical CTR

    Omaha, Nebraska

  • Velocity Clin Res Albuquerque

    Albuquerque, New Mexico

  • Albany Medical College

    Albany, New York

  • Carteret Medical Group

    Morehead City, North Carolina

  • Piedmont Healthcare/Research

    Statesville, North Carolina

  • Lillestol Research LLC

    Fargo, North Dakota

  • Triad Research Institute

    Norman, Oklahoma

  • Circuit Clinical - PMSI

    Pottstown, Pennsylvania

  • Clinical Res Collaborative

    Cumberland, Rhode Island

  • Velocity Clin Res Providence

    East Greenwich, Rhode Island

  • Velocity Clin Res Gaffney

    Gaffney, South Carolina

  • Holston Medical Group

    Kingsport, Tennessee

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.